Participants
| Role | Name | HCID | Charge |
|---|
| Reactant | Acetonitrile | HCID 6342 | — |
| Reactant | 4-(N-((2,4-diamino-6-pteridinyl)methyl)amino)benzoic acid | HCID 169748 | — |
| Reactant | L-glutamate(2-) | HCID 5460544 | — |
| Reactant | Pterin | HCID 135398660 | — |
| Catalyst | Zincchloride | HCID 3007855 | — |
| Solvent | Sodium Acetate | HCID 517045 | — |
| Product | Methotrexate | HCID 126941 | — |
Reaction Steps
Small samples (1 mg) of the end products of Examples 1 and 2 were treated at room temperature in 1M NaOAc (10 mL) containing ZnCl2 (10 mg) with freshly thawed carboxypeptidase G1 enzyme solution (0.3 μL, 4500 U/mL). In less than 15 min, glutamate hydrolysis was nearly complete according to HPLC analysis (20% MeCN 0.1M NH4OAc, pH 7.5), which showed the disappearance of >95% of the starting material (Example 1, 2.5 min; Example 2, 2.89 min) and the appearance of new peaks (3.0 and 3.3 min) assumed to be the 2-desamino and 2-desamino-2-methyl derivates of 4-amino-4-deoxypteroic acid, respectively. Under identical conditions, clinical grade methotrexate (mainly the L-form, 3.0 min) was cleaved to 4-amino-4-deoxy-N10 -methylpteroic acid (4.0 min), whereas D MTX (4.0 min, pre-formed from clinical grade MTX by carboxypeptidase G1 treatment) was resistant tc further treatment with the enzyme. Since the enzyme carboxypeptidase G1 is well known to cleave L-MTX to 4-amino-4-deoxy-N10 -methylpteroic acid under conditions that leave D-MTX unaffected, these results show that my desamino analogues are essentially pure L-enantiomers.
Provenance & Evidence
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|
| Patent number | US04956461 |
|---|
| Source dataset | uspto-grants-1990_09 |
|---|
| ORD ID | ord-7cd562cd343f4b4f99ff414b94e9ceeb |
|---|
| Source note | uspto-grants-1990_09 |
|---|